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National MS registries 
A B S T R A C T   
Background: Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease with an un-
predictable course that has a broad clinical spectrum and progresses over time. If a person with MS (PwMS) 
shows overall mild to moderate disability even after a long duration of disease, the term benign MS (BMS) is 
used. However, there is currently no generally accepted definition of BMS. Most definitions are based on EDSS in 
connection with disease duration, i.e. EDSS ≤3.0 after 15 years’ disease duration. The question arises whether 
focusing on EDSS alone is adequate for classifying the disease course taking into account that ‘hidden’ or ‘soft’ 
symptoms are not sufficiently covered by this instrument. The aims of the study are to assess the prevalence of 
BMS in one of the largest patient cohorts, to describe the prevalence of patients without disabilities and to assess 
the further disability progression of these patients over another 15 years. 
Methods: Based on data exported from the German MS Registry, PwMS with a disease duration of 15 years or 
more were included in the analyses. PwMS were divided into BMS (EDSS ≤3.0) or non-benign (NBMS, EDSS 
>3.0). 
Results: Out of 31,824 PwMS included in the German MS Register, we identified 10,874 patients with a disease 
duration ≥15 years of whom 4,511 (42%) showed an EDSS ≤3.0 fulfilling the criterion of benign MS. In the 
subgroup with EDSS measured exactly at 15 years’ disease duration, the proportion was 54%. This proportion 
decreased continuously with increasing disease duration and fell to 30% after 30 years. Female sex (hazard ratio 
[HR]: 0.84) was associated with BMS, while a progressive (HR: 2.09) and late disease onset (HR: 1.29) were 
associated with NBMS (p<0.001). With a more rigorous definition of BMS (EDSS ≤1.0, absence of disability, 
and active employment), only 580 (13%) of the initial BMS remained ‘benign’. 
Conclusion: Our data propose an alternative definition (EDSS ≤1.0, absence from any disability, and the ability 
to work after 15 years of disease duration) which might truly reflect BMS.   
1. Introduction 
Multiple sclerosis (MS) is a neuroinflammatory and neurodegen-
erative disease that primarily affects young adults. The disease follows 
an unpredictable course with a broad clinical spectrum and progresses 
over time (Krieger et al., 2016; Reich et al., 2018; Zettl et al., 2012). 
The search for prognostic factors to predict the course of the disease is 
essential, especially in view of the initiation and choice of disease- 
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modifying therapies (DMT) which have increasingly emerged over the 
last decades (Rommer et al., 2019). In general, more efficacious DMT 
have higher risks for severe adverse events, such as opportunistic in-
fections, secondary autoimmune complications, or infusion reactions. 
Therefore, there is a need for the definition of ‘benign MS’ that could 
allow to identify early predictive factors or biomarkers. A person with 
MS (PwMS) may show slight/moderate disabilities and limitations even 
after a long period of illness (Weinshenker et al., 1989). These patients 
usually are classified as benign, but currently, there is no generally 
accepted definition of this type of MS. Most definitions are based on 
EDSS (<3.5 or <4.0) in conjunction with a disease duration of 10–15 
years (Reynders et al., 2017). In this regard, it is important to note that 
a mere EDSS based definition has a strong focus on the patient´s mo-
bility, and the fact that ‘hidden’ or ‘soft’ symptoms such as fatigue, 
depression, cognitive dysfunction, and pain are not sufficiently covered 
(Meyer-Moock et al., 2014; Paul, 2016; Penner, 2016; Penner and 
Paul, 2017; von Bismarck et al., 2018). In particular fatigue is a dis-
abling and frequent symptom even in early disease stages and one of the 
most common across all stages of the disease (Rommer et al., 2019). 
These soft symptoms have a major impact on the patients’ well-being 
and work ability. The aims of the study are to assess the prevalence of 
BMS in one of the largest cohorts of patients worldwide, to describe 
symptoms and sociodemographic data, to assess patients without dis-
abilities who are still able to work after 15 years of illness, and to in-
vestigate subsequent progression of the disease once a patient has ful-
filled the common definition of BMS. 
2. Material and methods 
Based on data exported from the German MS Register (GMSR, www. 
msregister.de/en; March 2020), people with MS (PwMS) having a dis-
ease duration of 15 years or more were included in the analyses. Based 
on clinically assessed Expanded Disability Status Scale (EDSS) 
(Kurtzke, 1983), BMS classification was done as interval-censored time- 
to-event endpoint defined by the event of EDSS >3.0 (Amato et al., 
2008). The left side of the censoring interval is the last visit when the 
sustained EDSS was still ≤3.0 or zero if not observed. The right side is 
the first visit when the EDSS was sustained >3.0 or infinity if not ob-
served. Disease duration was calculated from the onset of the disease, 
but in cases where the onset of the disease is unknown, the date of 
diagnosis was used. 
The progression of disability, measured by EDSS and duration of the 
disease, was examined in regard to the association with other clinical as 
well as sociodemographic variables from the register. For longitudinal 
variables, the first visit after at least 15 years within the censoring in-
terval was chosen as the reference visit. For BMS this is the last visit 
(>15 years) when the (sustained) EDSS was still ≤3.0, and for NBMS, 
the first visit after at least 15 years of disease duration when the (sus-
tained) EDSS was >3.0. For data reconciliation, we allow an additional 
two months’ difference in time points. This approach allows the most 
coherent and real-world based comparison of the two (sub)cohorts, and 
the resulting difference in average disease duration was small. 
MRI activity is rated by a neurologist based on new T2 lesions and 
gadolinium enhancing lesions. Updating of MRI status in patients is 
often unregularly done, especially in older cohorts, and its extent of 
missingness in GMSR was reported. 
The GMSR collects the working status of PwMS and part-time and 
full-time employment were considered as employed, while early re-
tirement and unemployment were considered as unemployed. 
Payments or notifications from/in statutory pensions, education, do-
mestic work, or parental leave were treated as unclear / missing values 
in the analyses. Furthermore, to measure effects of early treatment 
exposure, the time to first DMT was analyzed. This analysis was only 
performed in patients who had complete DMT documentation in the 
GMSR available, a relapsing course, and an initiation of DMT within the 
first 15 years after disease onset. The absence of a disability was defined 
when no current symptoms that impair the patient were observed by a 
clinician. To investigate a more rigorous definition of truly benign MS, 
the absence of disability is used in conjunction with the ability to work, 
and an EDSS ≤1.0, which indicates abnormalities in neurological ex-
amination without suffering from symptoms (Kurtzke, 1983). 
Analyses on the time to EDSS >3.0 were done using univariable as 
well as multivariable interval-censored Cox proportional hazard model 
according to Pan, 1999. Descriptive figures and all analyses were per-
formed using R 3.6 (R core Team, Vienna), and group comparisons were 
done using 95% confidence intervals (CI), including Clopper-Pearson 
CI, chi-squared tests, or t-tests considering p-values of less than 5% 
statistically significant. Scatterplots of EDSS follow-up of BMS use 
beeswarm plot clustering whenever points would overlap and inter-
polation splines are estimated by generalized additive models for metric 
and binomial data. The GMSR has been registered at the German 
Clinical Trials Register (DRKS, Deutsches Register Klinischer Studien, 
No. DRKS00011257), and initial ethical approval was gained by the IRB 
at the University of Würzburg. 
3. Results 
Out of 31,824 PwMS from the German MS Register with an updated 
entry since 2014, we identified 10,874 PwMS with a disease duration 
≥15 years having a median date of onset in 1996 (IQR: 1990–2000). Of 
these, 4511 PwMS (41.5%) had an EDSS ≤3.0 after at least 15 years, as 
shown in Fig. 1. When considering discrete points in time, the pro-
portions with an EDSS ≤3.0 were 54% after exactly 15 years 
(n = 5082; rounded to whole years), and 30.0% after 30 years 
(n = 1195), see Fig. 2. 
3.1. Demographics 
BMS patients were younger at the onset of the disease and more 
often had a relapsing-remitting course. The employment level in the 
BMS cohort was higher (75%) than in the NBMS cohort (36%), the 
educational level showed higher rate of high school diploma in the BMS 
cohort (33.9%) than in the NBMS cohort (30.4%, p = 0.002). The 
average disease duration at the reference visit (last visit with EDSS 
≤3.0 after at least 15 years of disease) was 22.0 years in the BMS group 
compared to 23.7 years in the NBMS group at the reference visit (first 
visit with sustained EDSS >3.0 after 15 years). Table 1 provides an 
overview of the demographics of the PwMS analyzed. Data on treat-
ment status during the first 15 years after onset of the disease were 
Fig. 1. Flowchart of patients of the study.  
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available for 2530 patients. The time to first DMT was slightly shorter 
in the BMS cohort than in the NBMS cohort (6.5  ±  4.8 vs. 6.9  ±  4.9 
years, p = 0.04). 
In order to look at the whole cohort of patients with disease dura-
tion >15 years and associations with covariates, we analyzed the time 
to EDSS >3.0 (as event; interval-censored Cox proportional hazard 
model), with male PwMS and those with progressive onset (POMS) 
being less often benign (Fig. 2b/c). 
3.2. Predictive factors at onset of the disease 
Multivariable estimates of the Cox model showed that female sex 
was more likely to be associated with BMS, while a progressive and 
later disease onset is associated with NBMS (Table. 2). 
Cox model of symptoms at onset of disease showed that initial 
symptoms, such as paresis, bladder dysfunction, and cerebellar signs, 
were associated with a worse prognosis, while sensory signs or 
depression may be considered beneficial and were associated with a 
higher probability of BMS (Table 2). 
3.3. Association with other measurements of burden of disease 
Fig. 3 shows current symptoms in patients when they were still 
benign (reference visit; last visit after 15 years and EDSS ≤3.0) or first 
EDSS >3.0 in NBMS patients. It is evident that BMS differed from 
NBMS mainly in terms of walking problems, spasticity, and bladder 
dysfunction, which were more common in NBMS patients, while the 
differences in depression, fatigue, and cognition were smaller but still 
present. 
Taking all above-mentioned factors together, we defined truly be-
nign MS as follows: EDSS ≤1.0 after 15 years disease duration, absence 
from any disability (symptoms), and the ability to work. Applying these 
strict criteria, we identified 580 PwMS (13% of the original ‘benign MS’ 
cohort), PwMS, which can be described as truly benign (Fig. 4). 
3.4. EDSS progression within the BMS subgroup 
A crucial question when looking at the concept of BMS is how many 
PwMS remained benign for the next couple of years, and whether 
reaching the status of BMS might be a predictor for the subsequent 
disease course. Fig. 5 shows that 60% of PwMS with BMS and an age 
<50 years remained benign for another decade after the first date of 
being classified as benign. In older PwMS (age >50 years) this pro-
portion decreased significantly but was still around 40% (Fig. 5). Ap-
plying the strictest criteria (EDSS ≤1.0, absence of symptoms, and 
ability to work), about 70% of these patients remained benign for an-
other decade. 
Fig. 2. Cox-estimates of proportion of PwMS 
with EDSS ≤3.0 in the period from 15 to 50 
years of disease duration. Numbers of patients 
that are ‘at risk’, i.e. not having been docu-
mented with either sustained EDSS >3.0 or 
been lost to follow-up, given by disease dura-
tion in years (y) are: 6103 (20y), 3410 (25y), 
1714 (30y), 796 (35y), 338 (40y), 131 (45y), 
48 (50y). Covariables gender and type of onset 
are added in univariable analyses. For 107 
PwMS the type of onset is unclassifiable to re-
lapsing onset MS (roms) or progressive onset 
MS (poms). 
Table 1 
Comparison of benign and non-benign PwMS and subgroups of BMS when in-
stead of 15 years, 20 or 30 years disease duration were examined. Proportions 
along with Clopper-Pearson 95% confidence intervals or mean ( ± sd) are re-
ported. *Mean (median) time to diagnosis as the delay from manifestation of 
first symptoms to diagnosis of MS in years is given (p=0.14). **Time to first 
DMT is restricted to patients with complete DMT documentation, an observa-
tion period of up to 15 years after onset and calculated for RRMS only 
(p=0.04). All other statistical comparisons between BMS and NBMS were 
significant with p<0.01.        


































∅-Age onset 28.8 ( ± 8.4) 30.7 ( ± 9.4) 27.2  
( ± 7.6) 
24.2  
( ± 6.7) 
∅-Time to 
diagnosis* 
4.0 (0.7) 3.7 (0.6) 5.3 (1.0) 9.0 (5.0) 
∅-Disease duration 
(reference visit) 
22.0 ( ± 6.2) 23.6 ( ± 7.8) 26.3  
( ± 5.7) 
35.1  
( ± 5.0) 
∅-Age (last visit) 51.3 ( ± 9.1) 56.0 ( ± 9.8) 53.9  
( ± 8.3) 
59.7  





(n = 1353) 
25.0% 
[22.7-27.2%] 
(n = 1445) 
13.8% 
[11-16%] 
(n = 683) 
13.9% 
[8-19%] 
(n = 151) 
















∅-Time to first 
DMT**(years) 
6.5 ( ± 4.8) 
(n=1287) 
6.9 ( ± 4.9) 
(n=1243)      
Table 2 
Multivariable Cox regression effect estimates (HR) with interval-censored time 
to EDSS >3.0. Male gender, progressive onset, and later age at onset are as-
sociated with a faster EDSS progression. Multivariable models with adjustment 
for the three baseline covariates also are calculated for symptoms at onset of 
disease: pyramidal, cerebellar, brainstem, sensory, bladder, visual, depression, 
polysymptomatic.     
Baseline covariates (at onset of the disease) hazard ratio (HR) 
[95%-CI] 
p-value  
female gender 0.84 [0.79–0.89] <0.001 
age onset (10 years) 1.29 [1.25–1.34] <0.001 
progressive onset 2.09 [1.87–2.34] <0.001 
pyramidal 1.51 [1.37–1.66] <0.001 
cerebellar 1.10 [1.00–1.21] 0.05 
brainstem 1.04 [0.96–1.14] 0.3 
sensory 0.84 [0.78–0.90] <0.001 
bladder 1.39 [1.20–1.61] <0.001 
visual 1.01 [0.93–1.08] 0.9 
depression 0.86 [0.77–0.96] 0.009 
polysymptomatic 0.90 [0.81–1.00] 0.05    
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4. Discussion 
One of the most striking findings of our analysis is that although half 
of patients with a disease duration of 15 years and an EDSS ≤3.0 were 
classified as benign if the most common definition of BMS was followed 
(Amato et al., 2008). One in four of these patients was unemployed 
compared to 5% national unemployment rate in Germany (as of March 
2020). Moreover, the proportion of BMS in the overall sample de-
creased over time, and only about one in three remained benign after 
30 years. Thus, this definition seems not to truly reflect a benign course 
of the disease and underscores the need for an alternative definition. 
‘Benign’ MS was originally defined by Lublin and Reingold 
(Lublin and Reingold, 1996) as patients who are fully functional in all 
neurological systems 15 years after onset. The concept of BMS is not 
uniformly defined in the literature and is still a matter of debate 
(Reynders et al., 2017), and discussions are emerging whether or to 
what extent MS can be described as benign at all. Nevertheless, the 
clinical spectrum of MS is broad and there are certainly patients who 
are mobile and able to work after 15 years of disease 
(Weinshenker, 1994). 
The factors that tend to indicate a favorable or benign course in our 
analyses were a relapsing course, female sex, and earlier onset of the 
disease. Paresis and cerebellar symptoms at the onset of the disease 
were negative predictors, while sensory disorders were more likely to 
indicate a benign course. This is consistent with the literature, where 
female gender, younger age, and a relapsing disease course also in-
dicate a more favorable course, while dysfunction of the pyramidal 
tract and cerebellar involvement are associated with a more severe 
course (Bsteh et al., 2016; Confavreux et al., 2003; Weinshenker et al., 
1989). 
Age was a decisive factor in the long-term prognosis in patients with 
BMS, similarly as described in the Swedish cohort (Crielaard et al., 
2019). At an age of less than 50 years and 10 years additional follow- 
up, 60% of patients with BMS remained at EDSS ≤3.0, while at an age 
of over 50 years the proportion was below 40%. There are many rea-
sons for the role of age in disease progression. On the one hand, it might 
be that with increasing age and disease duration, the probability of 
suffering a progressive course increases (Mahad et al., 2015). On the 
other hand, it has recently been shown that with advancing age, phy-
sical symptoms occur that can be confused with MS symptoms even in 
individuals without any neurological disorder (Azevedo et al., 2019;  
Lynch et al., 2019). 
The already mentioned relatively high number of unemployed BMS 
patients, despite the rather low level of EDSS, makes the definition of 
BMS additionally come to the fore. The focus on EDSS in the current 
definition of BMS, which ignores soft or hidden symptoms such as fa-
tigue, cognition, and emotional disorders, may be a possible explana-
tion for this discrepancy. For example, Amato et al. showed that out of 
47 patients who met the definition of BMS, 11 patients suffered from 
cognitive impairment. In addition, Bsteh et al. (2016) demonstrated 
that neuropsychological disorders have a negative long-term influence 
on the disease outcome. These neuropsychological symptoms and fa-
tigue (Patejdl et al., 2016) may be present early in the course of the 
disease (von Bismarck et al., 2018), but are not adequately covered by 
the EDSS (Rommer et al., 2019). 
For this reason, the currently used definition of BMS is too broad, 
and the percentage of more than 50% in our sample and in other studies 
seems to be too high. We propose to introduce the following criteria for 
defining ‘truly’ benign MS: EDSS ≤1.0, absence of any disability, and 
able to work at least part-time. These criteria were chosen based on of 
the importance of employment in BMS patients (McAlpine, 1961) and 
the original definition that patients are fully functional in all neurologic 
systems 15 years after onset (Lublin and Reingold, 1996). Applying 
these criteria to our sample, the proportion of patients from the original 
4511 patients with BMS were reduced to only 580 patients (13%).  
Tallantyre et al. (2019) also aimed at describing truly benign MS pa-
tients. BMS patients were defined as having MS for at least 15 years; an 
EDSS <3.0; no significant fatigue, mood disturbance, cognitive im-
pairment, or disrupted employment; and had not received DMT. They 
found that only about 15% of their original population meet these 
criteria and the main reasons for the reduction were effects on em-
ployment and neuropsychological symptoms. Our figures showed a si-
milar decrease in the proportion of BMS patients with the additional 
criteria, although we did not select for the absence of DMT. In agree-
ment with Tallantyre et al. (2019), we did not see a relevant effect of 
time to first DMT in our analysis. The reason for this may be limited 
treatment options at manifestation for our cohort of patients whose 
Fig. 3. Symptoms at reference visit, i.e. upon reaching EDSS >3.0 (gray) or at last visit when still benign (green). All symptoms were more frequent in the non- 
benign group than in the benign group (p<0.001). 
Fig. 4. Venn-diagram of number of patients that might be truly benign.  
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disease onset was predominantly in the 1990s. Also, it remains unclear 
on whether a benign course would have caused the avoidance of DMT 
or whether an early DMT would have caused the course to be benign. 
Long-term availability of crucial time-varying confounders is needed to 
address this (Trojano et al., 2017). 
Limitations regarding the comparability of the NBMS group and the 
BMS group may apply. However, our choice of reference visit >15 
years disease duration, i.e. the last visit when BMS or the first visit 
when NBMS, resulted in a much higher similarity of both groups re-
garding disease duration and year of disease onset, compared to other 
studies (Crielaard et al., 2019). The question on how to classify a BMS 
patient who starts rapidly progressing after e.g. 20 or 25 years remains 
open. Most BMS were found to be stable, but Fig. 5 also reveals a certain 
amount of cases that may have lost their benignity in a relatively short 
amount of time. This may suggest that BMS could also be considered a 
status that could be lost (after being attained) or that is in general time- 
varying over the course of the disease. 
Our figures may indicate that employment status can be considered 
one of the most important indicators to classify BMS versus NBMS. 
Conversely, the factor with greatest impact on employment in MS pa-
tients is disability, which ranks ahead of education level, age and 
gender (Salter et al., 2020). 
5. Conclusion 
Approximately half of all MS patients suffer from BMS according to 
the most commonly used criteria. These criteria largely neglect neu-
ropsychological symptoms. With stricter application of BMS criteria 
(ability to work, absence of disability, and EDSS ≤1.0), the number of 
BMS patients decreased strongly to 13% of the original BMS cohort. 
Several reports and our data call for a redefinition of BMS. We propose 
a definition that includes an EDSS ≤1.0, absence from disability, and 
employment status (taking into account the employment market and 
age of the patients) after 15 years of disease duration. 
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